There are multiple points of a clinical trial’s route-map where the success of the study can be derailed. When it comes to sourcing comparator products to effectively assess an Investigational Product’s (IP) performance against the current standard of care, there’s a lot that can go wrong.

In this case study, we look at how one sponsor faced late stage design issues which put their clinical trial in jeopardy. Download today and discover how the Almac team was able to recover the clinical trial through their agile reaction and expertise in sourcing an alternative comparator drug.